Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APD791 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| APD791 | DRUG | APD791 or matching placebo in escalating doses |
APD791 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development, with completed trials assessing its safety and tolerability.
APD791 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
APD791 is in Phase 1 clinical development. Two Phase 1 trials in healthy volunteers have been completed, and the drug remains investigational, meaning it is not yet approved for any use.
APD791 has two completed Phase 1 trials: NCT00529646, a single-dose safety study in 90 healthy volunteers, and NCT00619931, a multiple-dose study in 50 healthy volunteers assessing safety, tolerability, and steady state pharmacokinetics.
APD791 is not FDA approved. It is an investigational drug that has completed Phase 1 trials in healthy volunteers, and it remains in clinical development.